EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,753 JPY | +2.71% |
|
-0.16% | -4.24% |
| May. 24 | BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea | MT |
| May. 16 | Eisai's Attributable Profit Falls 23.5% in Fiscal 2024 | MT |
| Sales 2024 | 742B 4.71B | Sales 2025 * | 768B 4.88B | Capitalization | 1,937B 12.3B |
|---|---|---|---|---|---|
| Net income 2024 | 42.41B 269M | Net income 2025 * | 49.61B 315M | EV / Sales 2024 | 2.21 x |
| Net cash position 2024 | 145B 923M | Net cash position 2025 * | 223B 1.42B | EV / Sales 2025 * | 2.23 x |
| P/E ratio 2024 |
42
x | P/E ratio 2025 * |
38.7
x | Employees | 11,076 |
| Yield 2024 |
2.57% | Yield 2025 * |
2.39% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +2.71% | ||
| 1 week | -0.16% | ||
| 1 month | +3.86% | ||
| 3 months | +7.98% | ||
| 6 months | -11.98% | ||
| Current year | -4.24% |
1 week
6 432.00
6 830.00
1 month
6 432.007 077.00
Current year
5 795.007 818.00
1 year
5 795.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
4 064.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 21-05-31 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 19 M€ | +11.22% | ||
| 1.23% | 240 M€ | +17.47% | ||
| 1.13% | 28,258 M€ | +15.99% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 6,753 | +2.71% | 1,967,300 |
| 24-05-30 | 6,575 | -1.37% | 1,299,700 |
| 24-05-29 | 6,666 | -1.02% | 879,300 |
| 24-05-28 | 6,735 | -0.68% | 860,300 |
| 24-05-27 | 6,781 | +0.25% | 875,500 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-11-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,753
JPY
Average target price
8,243
JPY
Spread / Average Target
+22.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.24% | 12.32B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 4523 Stock
